Literature DB >> 17172925

Myocardial blood flow and oxygen consumption in patients with Friedreich's ataxia prior to the onset of cardiomyopathy.

Shawn A Gregory1, Calum A MacRae, Kusai Aziz, Katherine B Sims, Jeremy D Schmahmann, Arash Kardan, Alexander M Morss, Patrick T Ellinor, Ahmed Tawakol, Alan J Fischman, Henry Gewirtz.   

Abstract

OBJECTIVES: We tested the hypothesis, in patients with Friedreich's ataxia and no overt structural heart disease, that impairment of cardiac oxidative metabolism may be compensated for either by increased rest myocardial blood flow or more efficient oxygen consumption in performance of external work.
BACKGROUND: Friedreich's ataxia is characterized by a mutant frataxin gene, which causes mitochondrial iron overload and impaired energy production. Further, it is frequently associated with cardiomyopathy. Studies using magnetic resonance spectroscopy, however, suggest impaired cardiac energetics even in the absence of structural heart disease.
METHODS: Positron emission tomography measured rest myocardial blood flow (N-13-ammonia method) and myocardial oxygen consumption (11-C-acetate, Kmono) in Friedreich's ataxia patients (n=8; 31+/-5 years, mean+/-SD, four women) and healthy controls (n=8; 30+/-7 years, five women) matched for stroke work index and age. Stroke work index and power were determined by electrocardiogram gated positron emission tomography N-13-ammonia using modified Simpson's rule to compute left ventricular volumes.
RESULTS: Neither stroke work index nor rest myocardial blood flow differed significantly between the groups. Although myocardial oxygen consumption was lower in Friedreich's ataxia (P<0.001), Kmono/rest myocardial blood flow, an index of myocardial oxygen extraction, did not differ between the groups. Power/Kmono, an index of the efficiency of myocardial oxygen consumption, was greater in Friedreich's ataxia (P<0.04). Rest myocardial blood flow normalized to rate pressure product was lower in Friedreich's ataxia (P<0.05).
CONCLUSIONS: Prior to the onset of cardiomyopathy, selected patients with Friedreich's ataxia may compensate for impaired cardiac energetics through more efficient oxygen consumption rather than increased rest myocardial blood flow. The data illustrate a more general mechanism pertaining to metabolic regulation of myocardial blood flow and myocardial oxygen consumption.

Entities:  

Mesh:

Year:  2007        PMID: 17172925     DOI: 10.1097/01.mca.0000236289.02178.60

Source DB:  PubMed          Journal:  Coron Artery Dis        ISSN: 0954-6928            Impact factor:   1.439


  6 in total

1.  [11C]Acetate rest-stress protocol to assess myocardial perfusion and oxygen consumption reserve in a model of congestive heart failure in rats.

Authors:  Etienne Croteau; Suzanne Gascon; M'hamed Bentourkia; Réjean Langlois; Jacques A Rousseau; Roger Lecomte; François Bénard
Journal:  Nucl Med Biol       Date:  2011-11-12       Impact factor: 2.408

Review 2.  PET measurement of adenosine stimulated absolute myocardial blood flow for physiological assessment of the coronary circulation.

Authors:  Henry Gewirtz
Journal:  J Nucl Cardiol       Date:  2012-04       Impact factor: 5.952

Review 3.  Regulating myocardial blood flow in health and disease.

Authors:  Henry Gewirtz
Journal:  Curr Cardiol Rep       Date:  2009-03       Impact factor: 2.931

4.  Phosphorus-31 two-dimensional chemical shift imaging in the myocardium of patients with late onset of Friedreich ataxia.

Authors:  Christian Wolf; Sylvia Boesch; Bernhard Metzler; Helga Weirich-Schwaiger; Thomas Trieb; Michael F H Schocke
Journal:  Mol Imaging Biol       Date:  2007-11-14       Impact factor: 3.488

5.  Myocardial ischemia in the absence of epicardial coronary artery disease in Friedreich's ataxia.

Authors:  Subha V Raman; Jennifer A Dickerson; Roula Al-Dahhak
Journal:  J Cardiovasc Magn Reson       Date:  2008-04-08       Impact factor: 5.364

Review 6.  Using Zebrafish for High-Throughput Screening of Novel Cardiovascular Drugs.

Authors:  Aaron Kithcart; Calum A MacRae
Journal:  JACC Basic Transl Sci       Date:  2017-02-27
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.